
view our CenterWatch profile

(click on poster for more details)
We work with leading pharmaceutical companies and CROs including:
Novartis Gets FDA Nod for Combo of Tekturna and Generic Norvasc
http://www.fdanews.com/newsletter/article?articleId=129874&issueId=14003
Merck Hits Impax With Patent Suit for Generic Vytorin Application
http://www.fdanews.com/newsletter/article?articleId=129875&issueId=14003
Pfizer Sues Actavis Over ANDA for Best-Selling Drug Lipitor
http://www.fdanews.com/newsletter/article?articleId=129876&issueId=14003
FDA Gives Mixed Judgment on Mesalamine Petitions
http://www.fdanews.com/newsletter/article?articleId=129877&issueId=14003
FDA Reveals First Generic Challenge to Celgene’s Cancer Drug Revlimid
http://www.fdanews.com/newsletter/article?articleId=129878&issueId=14003
Judge Blocks Generic Strattera Until Lilly’s Appeal is Heard
http://www.fdanews.com/newsletter/article?articleId=129879&issueId=14003
Judge Orders Watson CEO Bisaro to Testify in FTC Investigation
http://www.fdanews.com/newsletter/article?articleId=129880&issueId=14003
CMS Paid $43 Million for Drugs Considered Less-Than-Effective
http://www.fdanews.com/newsletter/article?articleId=129881&issueId=14003
Federal Court Refuses Sanofi Motion to Block Sale of Generic Lovenox
http://www.fdanews.com/newsletter/article?articleId=129882&issueId=14003
Watson False Marking Suit Is Latest in a Worrying Trend for Drugmakers
http://www.fdanews.com/newsletter/article?articleId=129883&issueId=14003